|
QNCX | Quince Therapeutics, Inc. |
|
|
QNCX | Quince Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.01 |
| Leverage | 99.04% |
| Market Cap | $ 156.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -56.8m |
| Margin | 8295.69% |
Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.